# Massachusetts Court Partially Denies Government FCA Motion

The U.S. District Court for the District of Massachusetts partially denied the government’s motion for summary judgment in its False Claims Act case against Regeneron Pharmaceuticals over alleged Medicare copay reimbursements for patients receiving Eylea. Judge F. Dennis Saylor IV found that the government’s false-certification claim did not require a more rigorous causation standard, but the ruling did not determine whether Regeneron violated the law. The case concerns potential liability tied to Medicare-related payments, not a contract award or new procurement opportunity.

- For government healthcare procurement teams and contractors, the case highlights litigation and compliance risk associated with arrangements connected to Medicare claims and reimbursements.
- Pharmaceutical companies and organizations supporting Medicare-reimbursed care can review how copay assistance and related reimbursement practices are documented; the ruling leaves the underlying liability questions unresolved.
- The decision does not announce a new procurement requirement, contract, or deadline.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** November 20, 2026

### Government Entities
- U.S. District Court for the District of Massachusetts
- United States government
- Medicare

### Vendors
- Regeneron Pharmaceuticals Inc. (Defendant in False Claims Act litigation)
